The NEO-CYT study is designed to evaluate MDNA11 as neoadjuvant immunotherapy before curative-intent surgery in earlier-stage melanoma patients whose immune systems may be more amenable to immunotherapy and more likely to benefit from treatment. MDNA11 will be evaluated in combination with nivolumab, with or without ipilimumab, with major pathologic response as a primary endpoint, which is considered predictive of long-term survival outcomes. NEO-CYT is sponsored by the non-profit Melanoma Foundation, Fonda ...